Simulations Plus has received a purchase order from the FDA to license the company's ADMET Predictor software.

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Environmental Protection Agency for its ADMET Predictor(TM) software.

Simulations Plus, Inc. (AMEX:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, unveiled a powerful new molecular design capability at the American Chemical Society national meeting in Chicago last week.

Simulations Plus, Inc. (AMEX:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that a large pharmaceutical company has signed a second multi-year global software license agreement.

Simulations Plus, Inc.